Abliva

Primary mitochondrial diseases

Primary mitochondrial diseases are metabolic diseases that affect the ability of cells to convert energy. The disorders can manifest differently depending on the organs affected and have historically been viewed as clinical syndromes,

Investor relations

Investors

Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company is focused on two projects.

Our team

Events and Presentations

Contact

Our partners and advisers

General meeting

Financial Calendar

Event

European Biotech Investor Days

Abliva participated at the virtual European Biotech Investor Days, Hosted by Solebury Trout, on 7 April 2021. CEO Ellen Donnelly presented the company.

See the presentation here

Directed new issue completed

News

Abliva

General meeting

Primary mitochondrial diseases

Investors

European Biotech Investor Days